Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study.

Renal insufficiency hemorrhage low molecular weight heparin pharmacokinetics tinzaparin

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 30 01 2024
revised: 19 06 2024
accepted: 08 07 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

Tinzaparin could be easier to manage than unfractionated heparin, in patients with severe renal impairment. However, clinical and pharmacological data regarding its use in such patients are lacking. The aims of this study were to determine, in patients with eGFR<30 mL.min We performed a retrospective observational single-center study, including in-patients with eGFR< 30 mL.min Over a 22-month period, 802 tinzaparin treatment periods in 623 patients were analysed: two-thirds received a prophylactic dose, 66% had an eGFR<20 mL.min Tinzaparin PK parameters and profiles were not affected by renal impairment. This suggests that tinzaparin, at therapeutic or prophylactic dose, could be an alternative to unfractionated heparin in hospitalized patients with severe renal impairment.

Sections du résumé

BACKGROUND BACKGROUND
Tinzaparin could be easier to manage than unfractionated heparin, in patients with severe renal impairment. However, clinical and pharmacological data regarding its use in such patients are lacking. The aims of this study were to determine, in patients with eGFR<30 mL.min
METHODS METHODS
We performed a retrospective observational single-center study, including in-patients with eGFR< 30 mL.min
RESULTS RESULTS
Over a 22-month period, 802 tinzaparin treatment periods in 623 patients were analysed: two-thirds received a prophylactic dose, 66% had an eGFR<20 mL.min
CONCLUSION CONCLUSIONS
Tinzaparin PK parameters and profiles were not affected by renal impairment. This suggests that tinzaparin, at therapeutic or prophylactic dose, could be an alternative to unfractionated heparin in hospitalized patients with severe renal impairment.

Identifiants

pubmed: 39019439
pii: S1538-7836(24)00423-9
doi: 10.1016/j.jtha.2024.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Isabelle Gouin-Thibault (I)

Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, France; IRSET-INSERM-1085, Univ Rennes, France. Electronic address: Isabelle.gouin@chu-rennes.fr.

Alexandre Mansour (A)

IRSET-INSERM-1085, Univ Rennes, France; Department of Anesthesia and Critical Care, Pontchaillou University Hospital of Rennes.

Charlène Caribotti (C)

Department of Pharmacy, Pontchaillou University Hospital of Rennes.

Morgane Pierre-Jean (M)

Univ Rennes, Pontchaillou University Hospital of Rennes, Inserm, LTSI - UMR 1099, Rennes.

Guillaume Bouzille (G)

Univ Rennes, Pontchaillou University Hospital of Rennes, Inserm, LTSI - UMR 1099, Rennes.

Alice Ballerie (A)

Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, 35000 Rennes, France.

Laure Maucorps (L)

Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, France.

Pierre Gueret (P)

Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, France.

Fabienne Nédelec-Gac (F)

Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, France.

Adeline Pontis (A)

Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, France; IRSET-INSERM-1085, Univ Rennes, France.

Guillaume Mahé (G)

Vascular Medicine Department, Radiology and Medical Imaging Department, Rennes University Hospital Centre, Rennes, France.

Stéphane Vannier (S)

Department of Neurology, University Hospital of Rennes, France.

Nathalie Behar (N)

Department of Cardiology, Rennes University Hospital, Rennes, France.

Isabelle Cardiet (I)

Department of Pharmacy, Pontchaillou University Hospital of Rennes.

Patrick Mismetti (P)

Therapeutic and Vascular Medecine Department, Saint-Etienne University Hospital; INSERM, U 1059 SAINBIOSE, Jean Monnet University, Mines Saint-Étienne.

Thierry Frouget (T)

Department of Nephrology, Pontchaillou University Hospital of Rennes.

Xavier Delavenne (X)

INSERM, U 1059 SAINBIOSE, Jean Monnet University, Mines Saint-Étienne; Department of Pharmacology, Saint-Etienne University Hospital.

Classifications MeSH